Cephalon, Inc.

Agreements reached with Barr Laboratories regarding PROVIGIL and ACTIQ patent litigation

Published in Physician Law Weekly, February 22nd, 2006

Cephalon, Inc., (CEPH) announced that it has entered into agreements with Barr Laboratories, Inc., to settle its pending patent infringement disputes in the United States related to PROVIGIL (modafinil) Tablets [C-IV] and ACTIQ (oral transmucosal fentanyl citrate) [C-II].

"This is a transformational event for Cephalon," said Frank Baldino, Jr., chairman and CEO. "Continued PROVIGIL sales provide a new foundation for further accelerating Cephalon's growth over the next several years."

In connection with the settlements, Cephalon will grant Barr a nonexclusive royalty-bearing right to market and sell a generic version of PROVIGIL in the United States....

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Physician Law Weekly

Source: Physician Law Weekly (2006-02-22)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry